AI Can Design a Drug. It Still Can't Get One Approved.
Generative AI is accelerating drug candidate design, but no AI-discovered molecule has reached approval because clinical trial execution and its regulatory footing remain unresolved.
The Clinical Trial Has No AI Rulebook
Sponsors are deploying AI across trial execution with no dedicated regulatory framework, leaving GCP and data integrity obligations to fill the gap alone.